DLDongwen Lv

Dongwen Lv

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dongwen Lv has a total of 269 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Discovery and Development of Covalent Activators: A Review

    by Amanda Wolbert, Dongwen Lv, Matteo Borgini

    While covalent drugs have traditionally been developed as inhibitors, an emerging class of molecules that enhance protein function through covalent modification is attracting increasing attention. This review provides a comprehensive overview of the discovery, design, and development of this class of molecules, surveying key examples across diverse protein families, including nuclear receptors, G Protein-Coupled Receptors (GPCRs), enzymes, and ion channels. We highlight both serendipitously discovered and rationally designed covalent activators, offering insights into their distinct mechanisms of action and enabling their classification into mechanistic categories. We discuss the molecular mechanisms underlying covalent activation, the electrophilic warheads used to achieve target engagement, and the experimental evidence supporting their activity. Particular emphasis is placed on distinguishing examples with therapeutic potential from those that primarily serve as chemical biology tools. Where available, the medicinal chemistry routes of representative covalent activators are discussed, with attention to key considerations in electrophilic warhead installation. While some covalent activators have demonstrated promising pharmacological properties, the field remains at an early stage of development, and the discovery and optimization of these molecules differ fundamentally from those of covalent inhibitors. Accordingly, this review seeks to identify common mechanistic and medicinal chemistry principles that underpin diverse classes of covalent activators. Through comparative analysis across different protein families, we highlight how target biology, structural information, and protein dynamics influence activation strategies, electrophile selection, and activator design, providing a framework that may guide the rational development of future covalent activators. Finally, we discuss emerging opportunities, challenges, and future directions in the discovery and development of covalent activators.

  • Development of PolyHis‐Targeting PROTAC Degraders

    by Hui Chen, Dong Zhu, Monica Billitti, Annan Sun, Lingtao Jin, Emily Moser, Nahid F. Mivechi, Guangrong Zheng, Dongwen Lv

    Targeted protein degradation (TPD) via proteolysis targeting chimeras (PROTACs) enables selective removal of proteins of interest (POIs) by hijacking the ubiquitin‐proteasome system (UPS). However, broad application is constrained by the availability of high‐quality target ligands, which remain scarce for much of the human proteome, limiting assessment of POIs for UPS‐mediated degradation. To address this challenge, we developed polyhistidine‐targeting PROTACs (polyHisTACs) by conjugating a nickel‐nitrilotriacetic acid (Ni 2 + ‐NTA) headgroup to ligands of VHL or CRBN, thereby recruiting these E3 ligase complexes to polyHis‐tagged POIs. As expected, polyHisTACs effectively degraded CRISPR‐engineered, endogenously polyHis‐tagged BRD4 and also induced robust degradation of an exogenously expressed polyHis‐tagged RNA‐binding protein, PSPC1, a target that is typically considered undruggable. In summary, polyHisTACs overcome key limitations of existing tag‐based degrader systems by leveraging a minimal, easily implemented polyHis tag. This platform provides a versatile, reliable way to evaluate UPS‐mediated degradability in the absence of target‐specific ligands and serves as a practical tool for acute POI depletion in basic research.


  • Development of PolyHis‐Targeting PROTAC Degraders

    by Hui Chen, Dong Zhu, Monica Billitti, Annan Sun, Lingtao Jin, Emily Moser, Nahid F. Mivechi, Guangrong Zheng, Dongwen Lv

    Targeted protein degradation (TPD) via proteolysis targeting chimeras (PROTACs) enables selective removal of proteins of interest (POIs) by hijacking the ubiquitin‐proteasome system (UPS). However, broad application is constrained by the availability of high‐quality target ligands, which remain scarce for much of the human proteome, limiting assessment of POIs for UPS‐mediated degradation. To address this challenge, we developed polyhistidine‐targeting PROTACs (polyHisTACs) by conjugating a nickel‐nitrilotriacetic acid (Ni 2 + ‐NTA) headgroup to ligands of VHL or CRBN, thereby recruiting these E3 ligase complexes to polyHis‐tagged POIs. As expected, polyHisTACs effectively degraded CRISPR‐engineered, endogenously polyHis‐tagged BRD4 and also induced robust degradation of an exogenously expressed polyHis‐tagged RNA‐binding protein, PSPC1, a target that is typically considered undruggable. In summary, polyHisTACs overcome key limitations of existing tag‐based degrader systems by leveraging a minimal, easily implemented polyHis tag. This platform provides a versatile, reliable way to evaluate UPS‐mediated degradability in the absence of target‐specific ligands and serves as a practical tool for acute POI depletion in basic research.


  • Open Access

    An unbiased proteomic platform for ATE1-based arginylation profiling

    by Zongtao Lin, Yixuan Xie, Joanna Gongora, Xingyu Liu, Emily Zahn, Bibhuti Bhusana Palai, Daniel H. Ramirez, Richard M. Searfoss, Francisca N. Vitorino, Rashmi Karki, et al.

    Protein arginylation is an essential post-translational modification catalyzed by arginyl-tRNA-protein transferase 1 (ATE1) in mammalian systems. Arginylation features a post-translational conjugation of an arginyl to a protein, making it extremely challenging to differentiate from translational arginine residues with the same mass. Here we present a general ATE1-based arginylation profiling platform for the unbiased discovery of arginylation substrates and their precise modification sites. This method integrates isotopic arginine labeling into an ATE1 assay utilizing biological lysates (ex vivo) rather than live cells, thus eliminating ribosomal bias and enabling bona fide arginylation identification. The method has been successfully applied to peptide, protein, cell, patient and mouse samples, with 235 unique arginylation sites revealed from human proteomes using 20 µg of input. Representative sites were validated and followed up for their biological functions. This global platform, applicable to various sample types, paves the way for functional studies of this difficult-to-characterize protein modification.


  • NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome

    by Amin Sobh, Elena Encinas, Alisha M Patel, Greeshma Surapaneni, Emilie Bonilla, Charlotte Leonie Kaestner, Janai Poullard, Monica Clerio, Karthik Vasan, Tzipporah Freeman, et al.

    Chromosomal translocation (4;14), an adverse prognostic factor in multiple myeloma (MM), drives overexpression of the histone methyltransferase nuclear receptor binding SET domain protein 2 (NSD2). A genome-wide CRISPR screen in MM cells identified adenylate kinase 2 (AK2), an enzyme critical for high-energy phosphate transfer from the mitochondria, as an NSD2-driven vulnerability. AK2 suppression in t(4;14) MM cells decreased nicotinamide adenine dinucleotide phosphate (NADP[H]) critical for conversion of ribonucleotides to deoxyribonucleosides, leading to replication stress, DNA damage, and apoptosis. Driving a large genome-wide increase in chromatin methylation, NSD2 overexpression depletes S-adenosylmethionine, compromising the synthesis of creatine from its precursor, guanidinoacetate. Creatine supplementation restored NADP(H) levels, reduced DNA damage, and rescued AK2-deficient t(4;14) MM cells. As the creatine phosphate shuttle constitutes an alternative means for mitochondrial high-energy phosphate transport, these results indicate that NSD2-driven creatine depletion underlies the hypersensitivity of t(4;14) MM cells to AK2 loss. Furthermore, AK2 depletion in t(4;14) cells impaired protein folding in the endoplasmic reticulum, consistent with impaired use of mitochondrial adenosine triphosphate (ATP). Accordingly, AK2 suppression increased the sensitivity of MM cells to proteasome inhibition. These findings delineate a novel mechanism in which aberrant transfer of carbon to the epigenome creates a metabolic vulnerability, with direct therapeutic implications for t(4;14) MM.


  • Open Access

    Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL

    by Digant Nayak, Dongwen Lv, Yaxia Yuan, Peiyi Zhang, Wanyi Hu, Anindita Nayak, Eliza A. Ruben, Zongyang Lv, Patrick Sung, Robert Hromas, et al.

    Overexpression of BCL-xL and BCL-2 play key roles in tumorigenesis and cancer drug resistance. Advances in PROTAC technology facilitated recent development of the first BCL-xL/BCL-2 dual degrader, 753b, a VHL-based degrader with improved potency and reduced toxicity compared to previous small molecule inhibitors. Here, we determine crystal structures of VHL/753b/BCL-xL and VHL/753b/BCL-2 ternary complexes. The two ternary complexes exhibit markedly different architectures that are accompanied by distinct networks of interactions at the VHL/753b-linker/target interfaces. The importance of these interfacial contacts is validated via functional analysis and informed subsequent rational and structure-guided design focused on the 753b linker and BCL-2/BCL-xL warhead. This results in the design of a degrader, WH244, with enhanced potency to degrade BCL-xL/BCL-2 in cells. Using biophysical assays followed by in cell activities, we are able to explain the enhanced target degradation of BCL-xL/BCL-2 in cells. Most PROTACs are empirically designed and lack structural studies, making it challenging to understand their modes of action and specificity. Our work presents a streamlined approach that combines rational design and structure-based insights backed with cell-based studies to develop effective PROTAC-based cancer therapeutics.


  • Open Access

    PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy

    by Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P. Master, Jiao Mo, Myung-Chul Kim, Yi Liu, Chandra K. Maharjan, Urvi M. Patel, Umasankar De, et al.

    An effective cancer therapy requires killing cancer cells and targeting the tumor microenvironment (TME). Searching for molecules critical for multiple cell types in the TME, we identified NR4A1 as one such molecule that can maintain the immune suppressive TME. Here, we establish NR4A1 as a valid target for cancer immunotherapy and describe a first-of-its-kind proteolysis-targeting chimera (PROTAC, named NR-V04) against NR4A1. NR-V04 degrades NR4A1 within hours in vitro and exhibits long-lasting NR4A1 degradation in tumors with an excellent safety profile. NR-V04 inhibits and frequently eradicates established tumors. At the mechanistic level, NR-V04 induces the tumor-infiltrating (TI) B cells and effector memory CD8+ T (Tem) cells and reduces monocytic myeloid-derived suppressor cells (m-MDSC), all of which are known to be clinically relevant immune cell populations in human melanomas. Overall, NR-V04–mediated NR4A1 degradation holds promise for enhancing anticancer immune responses and offers a new avenue for treating various types of cancers such as melanoma.


  • Bifunctional Peptide Nanofibrils for Targeted Protein Degradation

    by Zongtao Lin, Benjamin A. Garcia, Dongwen Lv

    Proteolysis targeting chimera (PROTAC) is a state‐of‐the‐art technology for ablating undruggable targets. A PROTAC degrader achieves targeted protein degradation (TPD) through the simultaneous binding of a protein of interest (POI) and an E3 ligase to form a ternary complex. A nanofibril‐based PROTAC strategy to form a polynary (E3)m : PROTAC : (POI)n complex has not been reported in the TPD field up to this point. A recent innovation shows that a POI ligand and E3 ligase ligand don't have to be within a fused degrader molecule. Instead, they can be recruited to cellular proximity by a self‐assembly‐driving peptide and click chemistry. The resulting nanofibrils can recruit multiple POI and E3 ligase molecules to form a polynary complex as a degradation center. The so‐called Nano‐PROTAC provides a novel approach for TPD in cancer therapy.

  • Bifunctional Peptide Nanofibrils for Targeted Protein Degradation

    by Zongtao Lin, Benjamin A. Garcia, Dongwen Lv

    Proteolysis targeting chimera (PROTAC) is a state‐of‐the‐art technology for ablating undruggable targets. A PROTAC degrader achieves targeted protein degradation (TPD) through the simultaneous binding of a protein of interest (POI) and an E3 ligase to form a ternary complex. A nanofibril‐based PROTAC strategy to form a polynary (E3)m : PROTAC : (POI)n complex has not been reported in the TPD field up to this point. A recent innovation shows that a POI ligand and E3 ligase ligand don't have to be within a fused degrader molecule. Instead, they can be recruited to cellular proximity by a self‐assembly‐driving peptide and click chemistry. The resulting nanofibrils can recruit multiple POI and E3 ligase molecules to form a polynary complex as a degradation center. The so‐called Nano‐PROTAC provides a novel approach for TPD in cancer therapy.


  • Piperlongumine conjugates induce targeted protein degradation

    by Jing Pei, Yufeng Xiao, Xingui Liu, Wanyi Hu, Amin Sobh, Yaxia Yuan, Shuo Zhou, Nan Hua, Samuel G. Mackintosh, Xuan Zhang, et al.